Coronavirus (COVID-19) Collection
CORTICOSTEROIDS IN THE TREATMENT OF SEVERE COVID-19 LUNG DISEASE: THE PULMONOLOGY PERSPECTIVE FROM THE FIRST UNITED STATES EPICENTER
As the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic first swept across the globe in the first quarter of 2020, the management of the associated clinical entity termed coronavirus disease 2019 (COVID-19) became the subject of institutional recommendations (Massachusetts General Hospital, 2020), societal guidelines (Bhimraj et al., 2020), and position statements (Russell et al, 2020). Because acute respiratory failure (ARF) in COVID-19 is triggered by a viral pathogen, it is understandable that the discussion of this potentially devastating illness has centered on its infectious disease and epidemiologic implications.From SARS to COVID-19: What we have learned about children infected with COVID-19
A cluster of patients presented with pneumonia caused by an unknown pathogen that was linked to the seafood wholesale market in Wuhan, China, in December 2019. Subsequently, a new coronavirus was identified by sequencing the whole genome of patient samples (Zhu et al., 2020a). It was named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by the Coronavirus Study Group (CSG) of the International Committee on Taxonomy of Viruses (Gorbalenya et al., 2020), and the disease caused by the virus was named coronavirus disease 2019 (COVID-19) by the World Health Organization (WHO).
